Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes

Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes

There is a need for countermeasures to mitigate lethal acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE). In WAG/RijCmcr rats, ARS occurs by 30-days following total body irradiation (TBI), and manifests as potentially lethal gastrointestinal (GI) and hematopoieti...

Full description

Bibliographic Details
Main Authors: Tracy Gasperetti, Tessa Miller, Feng Gao, Jayashree Narayanan, Elizabeth R. Jacobs, Aniko Szabo, George N. Cox, Christie M. Orschell, Brian L. Fish, Meetha Medhora
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Pharmacology
Subjects:
polypharmacy
acute radiation syndrome
delayed effects of acute radiation exposure
mitigation
hematopoietic growth factor
lisinopril
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.634477/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.634477/full

Similar Items